

Product Datasheet

Almonertinib mesylate

Catalog No. **BP-02147B** · CAS **2134096-06-1** · Form **salt · mesylate** · Physical state **other** · Color **Light yellow to yellow** · Version **1.0** · Revision **2026-09-03**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target EGFR	Research area Cancer
-----------------------	--------------------------------

Molecular formula **C₃₁H₃₉N₇O₅S**

Molecular weight **621.7500**

STRUCTURE



DESCRIPTION

Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer.

BIOLOGICAL ACTIVITY

In Vitro

HS-10296 mesylate is an orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity, which can be used to treat NSCLC[2]. Additionally, HS-10296 mesylate could also inhibit other EGFR sensitive mutations, including G719X, del19, L858R and L861Q.

SOLUBILITY

Soluble in DMSO 31.25 mg/mL

REFERENCES

- [1]. Yang JC, et al. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial [published online ahead of print, 2020 Sep 9]. J Thorac Oncol. 2020;S1556-0
- [2]. Sullivan I, et al. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front Med (Lausanne). 2017 Jan 18;3:76.